Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.

Core Evid · 2019 · PMC6503332 · PMID 31118877

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

57 The overall survival was 24.4 months for those with IDH1/2 mutations, but did not reach statistical significance to predict outcome for this group. 58 Given such robust responses, it may be of interest to study combinations of enasidenib with venetoclax + HMA or venetoclax alone.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.